Subject(s)
COVID-19/complications , Myocardial Infarction/pathology , Myocardial Infarction/virology , Adult , Echocardiography , Electrocardiography , Heart Septum/diagnostic imaging , Heart Septum/pathology , Humans , Magnetic Resonance Imaging , Male , Myocardial Infarction/diagnostic imaging , SARS-CoV-2 , Thrombosis/diagnostic imaging , Thrombosis/pathologyABSTRACT
Lopinavir-ritonavir combination is being used for the treatment of SARS-CoV-2 infection. A low dose of ritonavir is added to other protease inhibitors to take advantage of potent inhibition of cytochrome (CYP) P450 3A4, thereby significantly increasing the plasma concentration of coadministered lopinavir. Ritonavir also inhibits CYP2D6 and induces CYP2B6, CYP2C19, CYP2C9, and CYP1A2. This potent, time-dependent interference of major hepatic drug-metabolizing enzymes by ritonavir leads to several clinically important drug-drug interactions. A number of patients presenting with acute coronary syndrome and acute heart failure may have SARS-CoV-2 infection simultaneously. Lopinavir-ritonavir is added to their prescription of multiple cardiac medications leading to potential drug-drug interactions. Many cardiology, pulmonology, and intensivist physicians have never been exposed to clinical scenarios requiring co-prescription of cardiac and antiviral therapies. Therefore, it is essential to enumerate these drug-drug interactions, to avoid any serious drug toxicity, to consider alternate and safer drugs, and to ensure better patient care.
Subject(s)
COVID-19 Drug Treatment , Heart Diseases/drug therapy , Lopinavir/administration & dosage , Ritonavir/administration & dosage , SARS-CoV-2 , Anticoagulants/therapeutic use , Drug Interactions , Drug Therapy, Combination , Humans , Hypolipidemic Agents/therapeutic use , Platelet Aggregation Inhibitors/therapeutic useABSTRACT
Coronavirus infection outbreaks have occurred frequently in the last two decades and have led to significant mortality. Despite the focus on reducing mortality by preventing the spread of the virus, patients have died due to several other complications of the illness. The understanding of pathological mechanisms and their implications is continuously evolving. A number of symptoms occur in these patients due to the involvement of various endocrine glands. These clinical presentations went largely unnoticed during the first outbreak of severe acute respiratory syndrome (SARS) in 2002-2003. A few of these derangements continued during the convalescence phase and sometimes occurred after recovery. Similar pathological and biochemical changes are being reported with the novel coronavirus disease outbreak in 2020. In this review, we focus on these endocrine changes that have been reported in both SARS coronavirus and SARS coronavirus-2. As we battle the pandemic, it becomes imperative to address these underlying endocrine disturbances that are contributing towards or predicting mortality of these patients.